Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients

Kidney International

Volumn 82, Issue 1, 2012, Pages 100-105

  Sardiwal, Sunita ^a   Gardham, Clare ^a   Coleman, Adrian E ^b   Stevens, Paul E ^b   Delaney, Michael P ^b   Lamb, Edmund J ^a  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

bone; dialysis; hemodialysis; parathyroid hormone; renal osteodystrophy

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM CARBONATE; PARATHYROID HORMONE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84862506490     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.77     Document Type: Article

References (45)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953. (Pubitemid 43924257)
2. Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156. (Pubitemid 41828277)
3. Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 2007; 20: 139-143.
4. United Kingdom Renal Association Clinical practice guidelines, 4th edn. 2007.
5. Kidney Disease Improving Global Outcomes Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease related mineral and bone disorders (CKD-MBD) 2008.
6. Drueke TB. Is parathyroid hormone measurement useful for the diagnosis of renal bone disease? Kidney Int 2008; 73: 674-676. (Pubitemid 351323263)
7. Gardham C, Stevens PE, Delaney MP et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010; 5: 1261-1267.
8. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 27: 409-437.
9. Houillier P, Coste J, Froissart M. How many measurements to make a decision? Clin J Am Soc Nephrol 2010; 5: 1161-1162.
10. Urena P, Hruby M, Ferreira A et al. Plasma total vs. bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512. (Pubitemid 26128321)
11. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419. (Pubitemid 27156734)
12. Alvarez L, Ricos C, Peris P et al. Components of biological variation of biochemical markers of bone turnover in Paget0s bone disease. Bone 2000; 26: 571-576. (Pubitemid 30301648)
13. Panteghini M, Pagani F. Biological variation in bone-derived biochemical markers in serum. Scand J Clin Lab Invest 1995; 55: 609-616.
14. Scariano JK, Garry PJ, Montoya GD et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem 2001; 34: 639-644. (Pubitemid 34159355)
15. Hannon R, Blumsohn A, Naylor K et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998; 13: 1124-1133. (Pubitemid 28311780)
16. Ricos C, Iglesias N, Garcia-Lario JV et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007; 44: 343-352. (Pubitemid 351724670)
17. Teal TK, Reed M, Stevens PE et al. Stability of parathyroid hormone ex vivo in haemodialysis patients. Ann Clin Biochem 2003; 40: 191-193. (Pubitemid 36359876)
18. Vulpio C, Bossola M, Speranza D et al. Influence of blood sampling site on intact parathyroid hormone concentrations in hemodialysis patients. Clin Chem 2010; 56: 489-490.
19. Lamb EJ, Vickery S, Ellis AR. Parathyroid hormone, kidney disease, evidence and guidelines. Ann Clin Biochem 2007; 44: 1-4. (Pubitemid 46168794)
20. Brossard JH, Cloutier M, Roy L et al. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81: 3923-3929. (Pubitemid 26380397)
21. Moore C, Yee J, Malluche H et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1484-1493.
22. Drechsler C, Grootendorst DC, Boeschoten EW et al. Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. Nephrol Dial Transplant 2011; 26: 1340-1346.
23. Drechsler C, Krane V, Grootendorst DC et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant 2009; 24: 3151-3157.
24. Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777. (Pubitemid 351323258)
25. Ritz E, Malluche HH, Krempien B et al. Pathogenesis of renal osteodystrophy: roles of phosphate and skeletal resistance to PTH. Adv Exp Med Biol 1978; 103: 423-436.
26. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127.
27. Tangri N, Wagner M, Griffith JL et al. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis 2011; 57: 415-421.
28. Duarte ME, Peixoto AL, Pacheco AS et al. The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings. Sao Paulo Med J 1998; 116: 1790-1797.
29. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203.
30. Beddhu S, Baird B, Ma X et al. Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol 2010; 74: 91-96.
31. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-663.
32. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853. (Pubitemid 351664426)
33. Tanzy ME, Camacho PM. The effect of Vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia. Endocr Pract 2011; 17: 873-879.
34. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156. (Pubitemid 29256470)
35. Manghat P, Fraser WD, Wierzbicki AS et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2009; 21: 1853-1861.
36. Iimori S, Mori Y, Akita W et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients - a single-center cohort study. Nephrol Dial Transplant 2012; 27: 345-351.
37. Drechsler C, Verduijn M, Pilz S et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1752-1759.
38. Iba K, Takada J, Yamashita T. The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab 2004; 22: 594-596. (Pubitemid 39517880)
39. Lomashvili K, Garg P, O'Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 2006; 69: 1464-1470.
40. Shioi A, Katagi M, Okuno Y et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 2002; 91: 9-16. (Pubitemid 34778936)
41. Shantouf R, Kovesdy CP, Kim Y et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1106-1114.
42. Frazao JM, Martins P. Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 2009; 18: 303-307.
43. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254. (Pubitemid 46768608)
44. Tietz NW, Rinker AD, Shaw LM. IFCC methods for the measurement of catalytic concentration of enzymes Part 5. IFCC method for alkaline phosphatase (orthophosphoric-monoester phosphohydrolase, alkaline optimum, EC 3.1.3.1). J Clin Chem Clin Biochem 1983; 21: 731-748. (Pubitemid 14208514)
45. Tietz NW, Shuey DF. Reference intervals for alkaline phosphatase activity determined by the IFCC and AACC reference methods. Clin Chem 1986; 32: 1593-1594. (Pubitemid 17027803)